Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12178
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWong, Lih-Mingen
dc.contributor.authorToi, Antsen
dc.contributor.authorVan der Kwast, Theodorusen
dc.contributor.authorTrottier, Gregen
dc.contributor.authorAlibhai, Shabbir M Hen
dc.contributor.authorTimilshina, Narharien
dc.contributor.authorEvans, Andrewen
dc.contributor.authorZlotta, Alexandreen
dc.contributor.authorFleshner, Neilen
dc.contributor.authorFinelli, Antonioen
dc.date.accessioned2015-05-16T01:49:50Z
dc.date.available2015-05-16T01:49:50Z
dc.date.issued2014-04-15en
dc.identifier.citationThe Journal of Urology 2014; 192(4): 1088-93en
dc.identifier.govdoc24742593en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12178en
dc.description.abstractWe investigated the frequency of cancer and pathological progression in transition zone biopsies in men undergoing multiple rebiopsies while on active surveillance.Eligibility criteria of the active surveillance prostate cancer database (1997 to 2012) at our tertiary center includes prostate specific antigen 10 ng/ml or less, cT2 or less, no Gleason grade 4 or 5, 3 or fewer positive cores, no core with greater than 50% involvement, patient age 75 years or less and 1 or more biopsies after initial diagnostic biopsy. We excluded from analysis men with fewer than 10 cores at diagnostic biopsy and/or confirmatory biopsy greater than 24 months after diagnostic biopsy. Multiparametric magnetic resonance imaging was performed selectively to investigate incongruity between prostate specific antigen and biopsy findings. Pathological progression was defined by grade and/or volume (greater than 50% of core involved). Transition zone progression was subdivided into exclusively transition zone and combined transition zone (transition and peripheral zones). A multivariate Cox proportional hazards model was used to determine predictors of transition zone progression.A total of 392 men were considered in analysis. Median followup was 45.5 months. At each biopsy during active surveillance (confirmatory biopsy to biopsy 5+) there were transition zone positive cores in 18.6% to 26.7% of cases, all transition zone progression in 5.9% to 11.1% and exclusively transition zone progression in 2.7% to 6.7%. Volume related progression was noted more frequently than grade related progression (24 vs 9 cases). Predictors of only transition zone progression were the maximum percent in a single core (HR 1.99, 95% CI 1.30-3.04, p = 0.002) and cancer on magnetic resonance imaging (HR 3.19, 95% CI 1.23-8.27, p = 0.02).Across multiple active surveillance biopsies 2.7% to 6.7% of men had only transition zone progression. We recommend that transition zone biopsy be considered in all men at confirmatory biopsy. Positive magnetic resonance imaging findings or a high percent of core involvement may subsequently be useful to identify patients at risk.en
dc.language.isoenen
dc.subject.otherbiopsyen
dc.subject.othermagnetic resonance imagingen
dc.subject.otherneoplasm progressionen
dc.subject.otherprostateen
dc.subject.otherprostatic neoplasmsen
dc.subject.otherAgeden
dc.subject.otherBiopsy.methods.standardsen
dc.subject.otherDiagnosis, Differentialen
dc.subject.otherDisease Progressionen
dc.subject.otherFollow-Up Studiesen
dc.subject.otherHumansen
dc.subject.otherMagnetic Resonance Imagingen
dc.subject.otherMaleen
dc.subject.otherNeoplasm Gradingen
dc.subject.otherProstate.pathologyen
dc.subject.otherProstate-Specific Antigen.blooden
dc.subject.otherProstatic Neoplasms.blood.pathologyen
dc.subject.otherReproducibility of Resultsen
dc.subject.otherRetrospective Studiesen
dc.subject.otherTime Factorsen
dc.subject.otherWatchful Waiting.methodsen
dc.titleRegular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Journal of urologyen
dc.identifier.affiliationDivision of Surgical Oncology, Department of Uro-oncology, Princess Margaret Cancer Center, University Health Network; Department of Radiology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Department of Pathology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Urology, St. Vincent's Hospital and Austin Health, University of Melbourne, Victoria, Australiaen
dc.identifier.doi10.1016/j.juro.2014.04.010en
dc.description.pages1088-93en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24742593en
dc.type.austinJournal Articleen
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.